Glaucoma scales fail to impress

Article

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision.

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision, according to a report published in the August issue of Optometry & Vision Science.

Ecosse Lamoureux and colleagues from the University of Melbourne, Australia recruited glaucoma patients from private and public clinics to complete the IVI and GSS questionnaires. The two scales were assessed for fit to the Rasch model; specifically they were assessed for unidimensionality, individual item and person fit to the model, response category performance, differential item functioning and targeting of items to patients.

A total of 175 subjects were recruited, the majority of whom (65%) had primary open-angle glaucoma (POAG) and a visual acuity ≥6/9 in the better eye (87%). Only one third of the subjects had severe visual field loss in both eyes. Disordered thresholds were evident across all GSS items, indicating that the categories were difficult to discriminate and required category collapsing (five to three categories). Both scales demonstrated ineffective person-item targeting.

The authors believe that both IVI and GSS are ineffective scales for assessing glaucomatous patients who have good visual acuity.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.